ArticleJACC. Case reports2026
ST-Segment Elevation Myocardial Infarction Following Adalimumab Initiation in a Young Adult.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor necrosis factor alpha inhibitors have transformed management of autoimmune diseases, but cardiovascular safety profile of these diseases remains an area of investigation. CASE SUMMARY: A 39-year-old woman with rheumatoid arthritis presented with an ST-segment elevation myocardial infarction 3 weeks after initiating adalimumab therapy. Coronary angiography revealed a long thrombus in the mid left anterior descending coronary artery with preserved TIMI flow grade 3 and no coronary stenosis. A multidisciplinary team elected to pursue conservative management with glycoprotein IIb/IIIa inhibition (tirofiban) without stent placement given the patient's young age, absence of atherosclerotic plaque, and normal right and circumflex coronary arteries. Repeat angiography after 72 hours demonstrated complete thrombus resolution. DISCUSSION: This case raises the possibility of a prothrombotic effect linked to adalimumab. Registry data suggest a potential increased risk of thrombotic cardiovascular events with this medication. Clinicians should maintain a high index of suspicion for arterial thrombosis in patients receiving adalimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.